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ABSTRACT
It has been demonstrated that HLA-B*5701 screening reduces the risk for hypersensitivity reaction to abacavir 
in HIV-infected patients. Since B*5701 prevalence varies among different populations, it is important to de-
termine the carrier frequency prior to its use for the screening of HIV-infected patients. The aim of this study 
was to determine HLA-B*5701 carrier frequency in Chilean general population and HIV-infected patients 
referred for B*5701 typing. For that purpose 300 blood bank donors and 492 abacavir-naïve HIV-infected 
patients from Chile were screened for B*5701 by a sequence specifi c primer PCR. We detected 14/300 (4.7%) 
B*57-positive individuals in the Chilean general population, 11 (3.7%) were B*5701 positive, and 3 (1%) 
had another subtype. All were heterozygous, thus a B*5701 allele frequency of 2% was determined. Eleven of 
492 (2.2 %) HIV-patients carried a B*5701 allele. The difference between these frequencies is probably due 
to slow progression of HIV infection in HLA-B*5701 carriers, thus less patients would require antiretroviral 
therapy and B*5701 typing. Considering the usefulness of B*5701 screening, its prevalence in the Chilean 
general population, and the availability of a validated method, we conclude that HLA-B*5701 typing in Chil-
ean HIV-infected patients about to initiate abacavir treatment is strongly recommended.
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Abacavir is a nucleoside reverse-transcriptase 
inhibitor, with few drug interactions and a fa-
vorable safety profi le, therefore commonly used 
in combination with other antiretroviral agents 
as part of highly active antiretroviral treatment 
regimens. Approximately 5%-8% of human im-
munodefi ciency virus (HIV) infected patients on 
abacavir treatment develop a hypersensitivity re-
action (HSR) which usually occurs within the fi rst 
6 weeks of treatment.1 HSR is characterized by a 
multisystemic involvement that becomes more se-
vere with continuous dosing, requiring discontin-
uation of the drug. Subsequent rechallenge with 
abacavir must be avoided, since there is a high risk 
of developing a life threatening reaction.2 HSR in-
cidence varies among different populations, being 
more common in Caucasian patients than in those 
of African or Asian origin.3 Abacavir HSR occurs 
in approximately 4% of Chilean HIV–infected pa-
tients (Chilean AIDS Cohort, Carlos Beltran per-
sonal communication). 
Since 2002, many studies have reported a strong 
association between abacavir HSR and the class I 
human leukocyte antigen (HLA) allele B*5701.4,5 
More so, the utility of HLA-B*5701 screening as 
a pharmacogenetic test to predict the risk of de-
veloping HSR has been demonstrated in abacavir-
naïve HIV-infected patients.6,7 The incidence of 
HSR may vary substantially among different pop-
ulations due to the heterogeneity in HLA-B*5701 
prevalence across distinct ethnicities.3,8 Ideally, be-
fore implementing HLA-B*5701 genetic screen-
ing in a given population, its prevalence should be 
ascertained, particularly if it is unknown or poorly 
described, as in the Chilean population. Serologi-
cal methods for HLA-B57 detection lack specifi -
city and commercial molecular HLA-B typing 
methods used for identifying all known HLA-B 
alleles are expensive and laborious. Therefore 
the implementation of an alternate cost-effective 
method for HLA-B*5701 screening would be an 
appropriate approach to reduce the risk of devel-
oping HSR in the HIV positive patient population 
that is going to receive abacavir treatment. The 
aim of this study was to determine HLA-B*5701 
carrier frequency in Chilean general population 
and HIV-infected patients after implementing a 
typing method for HLA-B*5701 screening.
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In order to validate the method for B*5701 typing, 28 Exter-
nal Quality Control DNA samples from the College of Ameri-
can Pathologists (CAP) HLA-typing survey (2 B*5701 positive, 
26 B*57 negative), and 71 B*57 positive Chilean subjects (previ-
ously typed by a low resolution commercial method) were ana-
lyzed. To establish the B*5701 carrier frequency in Chilean gen-
eral population, 300 unrelated anonymised blood bank donors 
(150 men and 150 women) were typed. After implementation 
and validation of HLA-B*5701 molecular typing for routine 
clinical testing, 492 HIV-positive abacavir-naïve patients were 
referred to our laboratory for HLA-B*5701 screening prior ini-
tiating abacavir treatment. DNA from all samples was extracted 
by a standard “salting out” method.
A touch down PCR was implemented using the sequence 
specifi c primers (SSP) and conditions described by Martin 
et al.9 with minor modifi cations. The forward primer was 
synthesized without the M13 sequence tag, and the PCR 
cycling conditions were slightly different as the fi rst four 
cycles at 70°C annealing temperature were omitted. Also, 
a different target (the alpha-1-antitrypsin gen, AAT) was 
used as internal control of amplifi cation, using the primers 
AAT3 (5’-CCC ACC TTC CCC TCT CTC CAG GCA AAT 
GGG-3’) and AAT4 (5’-GGG CCT CAG TCC CAA CAT 
GGC TAA GAG GTG-3’) at a fi nal concentration of 2.5 µM. 
PCR products were subjected to electrophoresis on a 2% 
agarose gel stained with ethidium bromide and visualized 
under UV light. This multiplexed SSP-PCR allows the iden-
tifi cation of alleles carrying the generic B*57 and those with 
the subtype B*5701 by their amplicon sizes: the HLA-B*57 
group-specifi c primer pair amplifi es a 175 bp fragment, 
HLA-B*5701-subtype specifi c primers a fragment of 94 bp, 
and the internal control primers a 360 bp fragment. Given 
that this method only assesses the presence or absence of 
B*57 and B*5701 alleles, zygosity status could not be deter-
mined by this mean. Therefore a low resolution commercial 
typing method (Peel-Freez®SSP-UniTray® InvitrogenTM) 
was used to determine homozygosity or heterozygosity in 
the B*5701 positive samples. Allele and carrier frequencies 
for HLA-B*5701 were determined by direct gene counting 
and the data from both populations (i.e. general population 
and HIV patients) were analyzed by using the Chi-square 
test (MINITAB®14).10
The results obtained with the external quality control 
samples were 100% concordant with those reported by the 
CAP, and all 71 B*57 samples previously typed were correct-
ly identifi ed by the group-specifi c primers. Thus, this SSP-
PCR method was validated for routine analysis. See Figure 1 
for typical results. The B*5701 allele was present in 64 of 71 
(90%) B*57 positive subjects, the 7 remaining (10%) carried 
a different subtype. In the general population, from a total of 
300 subjects analyzed, 14 individuals (4.7 %) carried a B*57 
allele, from which 11 (3.7 %) were B*5701, and 3 (1.0%) had 
another subtype. The remaining 286 were negative for the 
Figure 1: Typical SSP-PCR results. M: 100 bp DNA size 
marker, S1: negative control for B*57 and B*5701 alleles, S2, 
S4, S6, and S7: samples positive for the B*5701 allele, S3 and 
S5: sample positive for B*57 group-specific amplification, 
carrying a different subtype.
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presence of this allele. All positive samples were heterozygotes, 
thus an allele frequency of 1.8 % for the B*5701 allele, and of 
0.5 % for the B*57 alleles with other subtypes was deter-
mined. Eleven (2.2%) out of 492 HIV patients were positive 
for the generic allele B*57, all of them were of the subtype 
B*5701 and heterozygotes for this allele as determined by 
low resolution typing. None of the B*5701 positive HIV pa-
tients was subsequently treated with abacavir. The results 
are summarized in Table 1. The observed B*5701 carrier 
and allele frequencies were higher in the general population 
sample than in HIV-infected patients. The statistical analysis 
performed using the Chi-square test to determine if this dif-
ference between both populations was noteworthy, revealed 
that it was not signifi cant (p < 0.05).
A prospective screening genetic test should fulfi ll sever-
al requirements before its introduction into routine clini-
cal practice, such as: improve the clinical outcome, have 
high predictive values, be cost-effective, and easy to imple-
ment technically.3 The clinical utility of B*5701 screening 
is well demonstrated, so technical aspects and feasibility of 
an analysis method were important to be evaluated. The 
PCR-based technique implemented here for HLA-B*5701 
screening proved to be 100% sensitive in detecting B*5701 
and B*57 positive alleles. It was also a method easy to im-
plement and to validate, as well as technically simple to 
perform in a clinical routine setting. More so, an “in house” 
PCR, properly validated as this one, allows cost reduction 
when compared to commercial kits, thus allowing its use 
also in developing countries where less fi nancial and tech-
nical resources are available. 
The observed B*5701 carrier frequency (3.7%) in this 
general population sample from Chile is in agreement with 
data (4.0%) from 70 Chilean individuals published at the 
“allele frequencies in worldwide populations” database.11 
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However, in this database there is no information about the 
status of those Chilean individuals (i.e. patients, controls 
or general population). Also, the B*57 carrier frequency 
published therein (1.0%) is much different than the one 
observed by us (4.7%), and unlikely to be correct, since the 
generic type of an allele cannot have a lower frequency than 
one of its subtypes. The fact that the B*5701 frequencies we 
observed in the general population and in the patient popu-
lation samples are lower than the ones reported for Cauca-
sians and higher than those in populations of Asian origin, is 
most likely due to our mixed genetic background of Cauca-
sian and Native American of mongoloid ancestry.12,13
To our knowledge, there are no B*5701 carrier or al-
lele frequencies described for HIV-positive patients from 
other Latin American countries, except for Hispanics in 
the United States.3 The carrier frequency found in our 
HIV-infected patients (2.2%) and in Chilean general 
population (3.7%) were very similar to the ones reported 
for US-Hispanics.8 The difference between HIV-infected 
patients and general population, although not statisti-
cally significant, could probably be related to the finding 
that HLA-B*5701 carriage has been associated with slow 
progression of HIV infection, therefore less patients car-
rying a HLA-B*5701 allele would require antiretroviral 
therapy and thus B*5701 typing.14,15 Considering the vast 
evidence on the benefits of B*5701 screening, its preva-
lence in the Chilean general population, and the avail-
ability of a proper screening method, B*5701 typing in 
Chilean HIV-infected patients about to initiate abacavir 
treatment is strongly recommended.
Table 1. HLA-B*57, B*5701 and other subtypes carrier and allele frequencies in Chilean population 
  General Chilean population  Chilean HIV patients 
  n = 300   n = 492
  n  Carrier Allele n Carrier Allele   
  frequency frequency  frequency frequency
B*57 (generic) 14 4.7% 2.3% 11 2.2% 1.1%
B*5701 (allele specific) 11 3.7% 1.8% 11 2.2% 1.1%
B*57__ (other subtype) 3 1.0% 0.5% 0 - -
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